Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) – Stock analysts at Jefferies Group upped their Q3 2017 earnings estimates for Pacira Pharmaceuticals in a research note issued on Wednesday. Jefferies Group analyst D. Steinberg now expects that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). Jefferies Group currently has a “Buy” rating and a $59.00 target price on the stock. Jefferies Group also issued estimates for Pacira Pharmaceuticals’ Q4 2017 earnings at $0.08 EPS and FY2017 earnings at ($0.65) EPS.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). The business had revenue of $70.90 million during the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.21 earnings per share.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/10/30/jefferies-group-weighs-in-on-pacira-pharmaceuticals-inc-s-q3-2017-earnings-pcrx.html.
Other analysts also recently issued reports about the company. Canaccord Genuity restated a “buy” rating and issued a $56.00 price objective on shares of Pacira Pharmaceuticals in a report on Monday, July 31st. Royal Bank Of Canada set a $58.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, July 30th. HC Wainwright set a $59.00 price objective on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Mizuho restated a “buy” rating and issued a $54.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, July 26th. Finally, Needham & Company LLC initiated coverage on Pacira Pharmaceuticals in a report on Tuesday, August 22nd. They issued a “buy” rating and a $55.00 price objective for the company. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $51.21.
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) opened at 33.20 on Monday. The stock has a 50 day moving average of $35.79 and a 200-day moving average of $41.94. Pacira Pharmaceuticals has a 52-week low of $29.81 and a 52-week high of $58.95. The stock’s market capitalization is $1.34 billion.
In other news, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the sale, the chief executive officer now owns 159,164 shares in the company, valued at $5,788,794.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the sale, the chief accounting officer now owns 21,312 shares in the company, valued at approximately $783,216. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock worth $1,215,480 in the last 90 days. Insiders own 6.60% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Pacira Pharmaceuticals by 9.2% during the second quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock worth $165,914,000 after acquiring an additional 294,494 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Pacira Pharmaceuticals by 7.4% during the second quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock worth $146,538,000 after acquiring an additional 211,982 shares during the last quarter. HealthCor Management L.P. grew its stake in shares of Pacira Pharmaceuticals by 63.1% during the second quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after acquiring an additional 693,799 shares during the last quarter. State Street Corp grew its stake in shares of Pacira Pharmaceuticals by 1.0% during the second quarter. State Street Corp now owns 1,118,083 shares of the company’s stock worth $53,340,000 after acquiring an additional 10,727 shares during the last quarter. Finally, Macquarie Group Ltd. grew its stake in shares of Pacira Pharmaceuticals by 1.6% during the second quarter. Macquarie Group Ltd. now owns 1,091,530 shares of the company’s stock worth $52,066,000 after acquiring an additional 16,760 shares during the last quarter.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
What are top analysts saying about Pacira Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pacira Pharmaceuticals Inc. and related companies.